bll posts
FeedPosted Jan 19th 2011 3:00PM by Eric Buscemi (RSS feed)
Filed under: Analyst Reports, Analyst Upgrades and Downgrades, Pfizer (PFE), Archer-Daniels-Midland (ADM), Comerica Inc (CMA), Merck and Co (MRK), U.S. Steel (X), Analyst Initiations
Analyst Upgrades
- Large Cap Pharmaceuticals sector upgraded to Overweight at Wells Fargo.
- Archer Daniels (ADM) upgraded to Outperform from Neutral at Credit Suisse.
- Cypress Semi (CY) upgraded to Buy from Neutral at UBS.
- MFA Financial (MFA) upgraded to Buy from Hold at Jefferies.
- Blackstone (BX) upgraded to Buy from Hold at Jefferies.
- Comerica (CMA) upgraded to Hold from Sell at Citigroup.
- Dollar Tree (DLTR) upgraded to Overweight from Equal Weight at Morgan Stanley.
- NuVasive (NUVA) upgraded to Outperform from Market Perform at Leerink.
- Cogdell Spencer (CSA) upgraded to Buy from Hold at Jefferies.
- Hersha Hospitality (HT) upgraded to Hold from Underperform at Jefferies.
- G&K Services (GKSR) upgraded to Outperform from Neutral at RW Baird.
- Graham Packaging (GRM) upgraded to Buy from Neutral at Goldman.
- Shaw (SJR) upgraded to Neutral from Underperform at BofA/Merrill.
Continue reading Analyst Calls: ADM, BX, BZH, CMA, DLTR, MRK, NE, PFE, X ...
Posted Dec 11th 2008 11:41AM by Eric Buscemi (RSS feed)
Filed under: Analyst Upgrades and Downgrades, Intel (INTC), Viacom (VIA), Analyst Initiations, Rio Tinto plc ADS (RIO)
Analyst upgrades:
- Citigroup upgraded shares of Ball (NYSE: BLL) to Buy from Hold and raised its target to $45 from $41 as they believe recent capacity closures will be positive for beverage can operating rates.
- Deutsche Bank upgraded Rio Tinto (NYSE: RTP) to Buy from Hold on valuation and the company's plans to preserve cash.
- ThinkPanmure upgraded Intel (NASDAQ: INTC) to Accumulate from Sell and raised its target to $17 from $12 citing trough earnings in 2009 and lowered expectations.
- Viacom B (NYSE: VIA.B) was added to Goldman's Conviction Buy List.
- Telefonica (NYSE: TEF) was upgraded to Outperform from Neutral at Credit Suisse.
- Onyx Pharma (NASDAQ: ONXX) was raised to Overweight from Neutral at JP Morgan.
Analyst downgrades:Continue reading Analyst calls: RTP, INTC, VIA.B, TEF, BRCD, JBL, ERIC, CEPH ...